Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $963,529.41 today based on a ...

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers. Did you ...

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

This was the stock's second consecutive day of gains.

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

Processing approximately one-third of the adult U.S. population's lab tests annually, Quest Diagnostics (NYSE ... NeoGenomics had the weakest performance against analyst estimates among its peers. The ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Penumbra Inc (NYSE: PEN ): Adam Elsesser, CEO and President, sold shares totaling approximately $4.5 million at prices ranging from $267.36 to $277.63 per share. Elsesser also exercised stock options ...